The burden of Cancer is expected to be touching 24 million new cases in the next 20 years. Even though the cases are increasing, the fatality rate has decreased and the life expectancy has increased across a variety of cancers in the last few decades. With an increase in the spending on oncology clinical trials, we have also seen a significant increase in the speed of the clinical trials being conducted.
This has been possible only because of the breakthrough therapy designation for experimental drugs by the FDA. With this increased number of clinical trials, there are newer challenges being faced by the researchers.
In his Key-Note Speech, hear Mr. Suresh Ramu talk about the challenges faced, and the need of newer statistical approaches required to make a difference in the lives of the many people who are already affected by the disease and for those who might get affected in the future.